A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps

NCT05866614 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 881

Last updated 2026-03-31

No results posted yet for this study

Summary

This is an observational, prospective cohort study to evaluate the safety of Remsima® SC in the treatment of RA, AS, PsA and Ps.

Conditions

Interventions

DRUG

Remsima IV

Patient will be treated with Remsima IV as per the SmPC or

DRUG

Remsima SC

Patient will be treated with Remsima SC as per the SmPC

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-13
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05866614 on ClinicalTrials.gov